Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Is Now Thoroughly Derisked
12:16pm, Monday, 30'th Dec 2024
Ocular Therapeutics' OTX-TKI implant offers a cost-effective, long-lasting alternative to gene therapies for wet AMD, showing superior duration and comparable efficacy to Regeneron's Eylea. Recent FDA
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 13'th Dec 2024
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the developm
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 10'th Dec 2024
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
07:30am, Monday, 02'nd Dec 2024
SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrationa
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
07:30am, Tuesday, 26'th Nov 2024
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
09:41am, Thursday, 14'th Nov 2024
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.51 per share a year ago.
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
07:30am, Wednesday, 13'th Nov 2024
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
07:30am, Wednesday, 06'th Nov 2024
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the develop
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
07:30am, Tuesday, 15'th Oct 2024
SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therape
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
11:00am, Monday, 14'th Oct 2024
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
05:50am, Friday, 11'th Oct 2024
In my previous article, I rated Ocular as a “Hold” based on concerns regarding Axpaxli's path to market. The SOL-1 and SOL-R Phase III trials are designed to assess Axpaxli's safety, efficacy, and
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 09'th Oct 2024
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the developm
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
07:30am, Wednesday, 09'th Oct 2024
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the develop
Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
07:30am, Wednesday, 25'th Sep 2024
BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world
Ocular Therapeutix™ to Present at September Retina Meetings
07:30am, Thursday, 05'th Sep 2024
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the develo
